2020 had an impact on nearly every industry around the world in 2021, with effects that will likely continue to ripple well into 2022 and possibly the years beyond. Arguably one of the industries that saw the largest shifts related directly to the events of 2020 were the Pharma and Biopharma sectors. From public perception to investor interest, the unprecedented events had a number of impacts on our industries. To celebrate the 40th episode of "The Weekly Bioanalysis", Dom and John are joined by the CEO of KCAS, John Bucksath, to discuss these impacts and specifically the changes we've experienced here at KCAS within the last year or so, and what it means for the years to come!